Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S105-12
Date
03/27/2007Pubmed ID
17382019DOI
10.3816/clm.2007.s.010Scopus ID
2-s2.0-34249653546 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.
Author List
Atallah E, Kantarjian H, Cortes JAuthor
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
BenzamidesClinical Trials as Topic
Follow-Up Studies
Humans
Imatinib Mesylate
Neoplasms
Piperazines
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl
Pyrimidines
Time Factors
United States
United States Food and Drug Administration